References
Forman L, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002:889–896. doi:10.1053/gast.2002.32418.
Roche B, Sebagh M, Canfora ML, et al. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl. 2008:1766–1777. doi:10.1002/lt.21635.
Gane EJ, Agarwal K. Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: “a flood of opportunity.” Am J Transplant. 2014:994–1002. doi:10.1111/ajt.12714.
Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002;353. doi:10.1053/jhep.2002.31773.
Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology.. 2015;148:e1.
Gambato M, Pèrez-Del-Pulgar S, Hedskog C, et al. Hepatitis C virus RNA persists in liver explants of most patients awaiting liver transplantation treated with an interferon-free regimen. Gastroenterology. 2016;151:e3.
Stöhr S, Costa R, Sandmann L, et al. Host cell mTORC1 is required for HCV RNA replication. Gut. 2016;65:2017–2028.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors who have taken part in this study declare that they have nothing to disclose regarding funding or conflict of interest with respect to this manuscript.
Rights and permissions
About this article
Cite this article
Lenci, I., Bosa, A., Milana, M. et al. Evidence of Spontaneous Post-transplant HCV Eradication in Two Failed DAA Treatments Awaiting Liver Transplantation. Dig Dis Sci 62, 2193–2195 (2017). https://doi.org/10.1007/s10620-017-4594-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-017-4594-y